Research programme: tryptophan 2,3-dioxygenase inhibitors - iTeos Therapeutics
Latest Information Update: 11 Dec 2014
At a glance
- Originator iTeos Therapeutics
- Developer iTeos Therapeutics; Ludwig Institute for Cancer Research
- Class Small molecules
- Mechanism of Action Tryptophan oxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer